Trial · NCT02698189
Results by group219
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 219
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Dose Limiting Toxicity (DLT) | MK-8628 20 mg AML Cohort | 0.00 | Percentage of participants | ||
| Percentage of Participants With a Dose Limiting Toxicity (DLT) | MK-8628 20 mg DLBCL Cohort | 16.67 | Percentage of participants | ||
| Percentage of Participants Who Experienced At Least One Adverse Event (AE) | MK-8628 20 mg AML Cohort | 100.0 | Percentage of participants | ||
| Percentage of Participants Who Experienced At Least One Adverse Event (AE) | MK-8628 20 mg DLBCL Cohort | 100.0 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 20 mg AML Cohort | 0.0 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 20 mg DLBCL Cohort | 0.0 | Percentage of participants | ||
| Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010) | MK-8628 20 mg AML Cohort | Complete response | 0.0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants |
| Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010) | MK-8628 20 mg AML Cohort | Partial response | 0.0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants |
| Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014) | MK-8628 20 mg DLBCL Cohort | Complete response | 0.0 | 95% Confidence Interval 0.0 to 45.9 | Percentage of participants |
| Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014) | MK-8628 20 mg DLBCL Cohort | Partial response | 16.7 | 95% Confidence Interval 0.4 to 64.1 | Percentage of participants |
| Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010) | MK-8628 20 mg AML Cohort | Complete response | 0.0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants |
| Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010) | MK-8628 20 mg AML Cohort | Partial response | 0.0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants |
| Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010) | MK-8628 20 mg AML Cohort | Stable disease | 0.0 | 95% Confidence Interval 0.0 to 70.8 | Percentage of participants |
| Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014) | MK-8628 20 mg DLBCL Cohort | Complete response | 0.0 | 95% Confidence Interval 0.0 to 45.9 | Percentage of participants |
| Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014) | MK-8628 20 mg DLBCL Cohort | Partial response | 16.7 | 95% Confidence Interval 0.4 to 64.1 | Percentage of participants |
| Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014) | MK-8628 20 mg DLBCL Cohort | Stable disease | 0.0 | 95% Confidence Interval 0.0 to 45.9 | Percentage of participants |
| Observed Maximum Concentration (Cmax) of MK-8628 | MK-8628 20 mg AML+DLBCL Cohorts | 360 | Standard Deviation 132 | ng/mL | |
| Time to Maximum Concentration (Tmax) of MK-8628 | MK-8628 20 mg AML+DLBCL Cohorts | 2.25 | Full Range 1.00 to 8.00 | hr | |
| Observed Minimum Concentration (Cmin) of MK-8628 | MK-8628 20 mg AML+DLBCL Cohorts | 134 | Standard Deviation 77.2 | ng/mL | |
| Area Under the Concentration-Time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞) | MK-8628 20 mg AML+DLBCL Cohorts | 3580 | Standard Deviation 1340 | hr*ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02698189/results